Li Sophie, Zheng Guibin, Xu Li, Goswami Maitrayee, Zafereo Mark E, Sherman Steven I, Li Guojun, Sturgis Erich M, Wang Jennifer R
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
School of Medicine, Baylor College of Medicine, Houston, Texas.
JAMA Otolaryngol Head Neck Surg. 2025 Feb 1;151(2):113-120. doi: 10.1001/jamaoto.2024.3963.
Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important to determine whether patients with higher germline genetic risk, as summarized using PGS, present with more aggressive disease and/or develop worse clinical outcomes.
To assess whether germline risk defined by PGS is associated with clinicopathologic features and survival outcomes for patients with PTC.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with newly diagnosed PTC who presented to The University of Texas MD Anderson Cancer Center for treatment between 1999 and 2014, with a median follow-up of 12 years. Data were analyzed from December 2023 to April 2024.
Germline risk, as defined by PGS.
Genomic DNA was extracted from buffy coat cells isolated from peripheral blood samples, and genotyping for germline polymorphisms was performed. Germline risk for PTC was estimated with a previously validated PGS calculated from 10 single-nucleotide variations identified through genome-wide association studies. Stage; PTC-specific survival, defined as the time from PTC diagnosis to death caused by PTC; and overall survival, defined as the time from PTC diagnosis to death by any cause, were analyzed.
A total of 366 patients were included in the study (261 women [71.3%]; mean [SD] age at diagnosis, 44.3 [13.8] years). There was a statistically significant association between higher PGS and multifocality (β [SE], 0.40 [0.23]; P = .045) and cervical lymph node involvement (N stage) (β [SE], 0.62 [0.35]; P = .009) at diagnosis. PGS was associated with PTC-specific survival (hazard ratio, 2.66; 95% CI, 1.03-6.85; P = .04), but this association was not independent of age and overall stage. There was not a statistically significant association between PGS and overall survival.
Findings of this cohort study suggest that patients with a higher germline risk of PTC, as estimated by PGS, present with more aggressive clinicopathologic features. These results contribute to the current understanding of inherited risk in PTC and how germline variants could potentially contribute to disease presentation and clinical outcomes.
全基因组关联研究已确定与乳头状甲状腺癌(PTC)发生相关的种系变异,可用于构建多基因评分(PGS)。确定使用PGS总结的种系遗传风险较高的患者是否表现出更具侵袭性的疾病和/或出现更差的临床结局非常重要。
评估PGS定义的种系风险是否与PTC患者的临床病理特征和生存结局相关。
设计、设置和参与者:这项回顾性队列研究纳入了1999年至2014年间到德克萨斯大学MD安德森癌症中心就诊接受治疗的新诊断PTC患者,中位随访时间为12年。数据于2023年12月至2024年4月进行分析。
PGS定义的种系风险。
从外周血样本中分离的血沉棕黄层细胞中提取基因组DNA,并进行种系多态性基因分型。通过先前验证的PGS估计PTC的种系风险,该PGS由通过全基因组关联研究确定的10个单核苷酸变异计算得出。分析了分期;PTC特异性生存,定义为从PTC诊断到因PTC死亡的时间;以及总生存,定义为从PTC诊断到因任何原因死亡的时间。
本研究共纳入366例患者(261例女性[71.3%];诊断时的平均[标准差]年龄为44.3[13.8]岁)。较高的PGS与诊断时的多灶性(β[标准误],0.40[0.23];P = 0.045)和颈部淋巴结受累(N分期)(β[标准误],0.62[0.35];P = 0.009)之间存在统计学显著关联。PGS与PTC特异性生存相关(风险比,2.66;95%置信区间,1.03 - 6.85;P = 0.04),但这种关联并非独立于年龄和总体分期。PGS与总生存之间没有统计学显著关联。
这项队列研究的结果表明,通过PGS估计的PTC种系风险较高的患者表现出更具侵袭性的临床病理特征。这些结果有助于当前对PTC遗传风险的理解,以及种系变异如何可能影响疾病表现和临床结局。